The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity
Open accessAbstract
Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol synthesis, and are widely used to treat hypercholesterolemia. These drugs can lead to a number of side effects in muscle, including muscle fiber breakdown; however, the mechanisms of muscle injury by statins are poorly understood. We report that lovastatin induced the expression of atrogin-1, a key gene involved in skeletal muscle atrophy, in humans with statin myopathy, in zebrafish embryos, and in vitro in murine skeletal muscle cells. In cultured mouse myotubes, atrogin-1 induction following lovastatin treatment was accompanied by distinct morphological changes, largely absent in atrogin-1 null cells. In zebrafish embryos, lovastatin promoted muscle fiber damage, an effect that was closely mimicked by knockdown of zebrafish HMG-CoA reductase. Moreover, atrogin-1 knockdown in zebrafish embryos prevented lovastatin-induced muscle injury. Finally, overexpression of PGC-1alpha, a transcriptional coactivator that induces mitochondrial biogenesis and protects against the development of muscle atrophy, dramatically prevented lovastatin-induced muscle damage and abrogated atrogin-1 induction both in fish and in cultured mouse myotubes. Collectively, our human, animal, and in vitro findings shed light on the molecular mechanism of statin-induced myopathy and suggest that atrogin-1 may be a critical mediator of the muscle damage induced by statins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stages of embryonic development of the zebrafish
Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B., & Schilling, T. F. (1995) · Developmental Dynamics · doi:10.1002/aja.1002030302 · Cited by 12,037
The zebrafish book : a guide for the laboratory use of zebrafish (Danio rerio)
Westerfield, M. (1995) · Medical Entomology and Zoology · Cited by 6,813
A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
Self-citationTranscriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres
Lin, J., Wu, H., Tarr, P. T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., Isotani, E., Olson, E. N., et al. (2002) · Nature · doi:10.1038/nature00904 · Cited by 2,546
Metabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130
Patti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., Kohane, I., Costello, M., Saccone, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1032913100 · Cited by 1,952
Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy
Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A., & Goldberg, A. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251541198 · Cited by 1,774
Self-citationMultiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539
Self-citationThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Metabolic profiles of three fiber types of skeletal muscle in guinea pigs and rabbits
Peter, J. B., Barnard, R. J., Edgerton, V. R., Gillespie, C. A., & Stempel, K. E. (1972) · Biochemistry · doi:10.1021/bi00764a013 · Cited by 1,313
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Mechanisms of Muscle Wasting — The Role of the Ubiquitin–Proteasome Pathway
Mitch, W. E., & Goldberg, A. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612193352507 · Cited by 1,166
Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1
Baar, K., Wende, A. R., Jones, T. E., Marison, M., Nolte, L. A., Chen, M., Kelly, D. P., & Holloszy, J. O. (2002) · The FASEB Journal · doi:10.1096/fj.02-0367com · Cited by 1,020
Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974
Self-citationIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · cited 2×
“Some statins, such as cerivastatin, have especially marked toxicity in skeletal muscle and have been removed from clinical use (1, 4).”
Handschin, C., Rhee, J., Lin, J., Tarr, P. T., & Spiegelman, B. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1232352100 · Cited by 729
Mootha, V. K., Handschin, C., Arlow, D., Xie, X., St. Pierre, J., Sihag, S., Yang, W., Altshuler, D., Puigserver, P., Patterson, N., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401401101 · Cited by 688
Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
Identification of separate slow and fast muscle precursor cells in vivo, prior to somite formation
Devoto, S. H., Melançon, E., Eisen, J. S., & Westerfield, M. (1996) · Development · doi:10.1242/dev.122.11.3371 · Cited by 666
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Sacheck, J. M., Ohtsuka, A., McLary, S. C., & Goldberg, A. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2004 · Cited by 606
Sacheck, J. M., Hyatt, J. K., Raffaello, A., Thomas Jagoe, R., Roy, R. R., Reggie Edgerton, V., Lecker, S. H., & Goldberg, A. L. (2007) · The FASEB Journal · doi:10.1096/fj.06-6604com · Cited by 585 · cited 4×
“In these conditions, muscle protein is rapidly mobilized through a common cellular mechanism involving similar biochemical and transcriptional adaptations, including activation of the ubiquitin proteasome pathway (UPP), the main intracellular system for protein degradation (20, 21).”
InfluentialSelf-citationStatin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Self-citationCancer cachexia is regulated by selective targeting of skeletal muscle gene products
Acharyya, S., Ladner, K. J., Nelsen, L. L., Damrauer, J., Reiser, P. J., Swoap, S., & Guttridge, D. C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420174 · Cited by 542
Analysis of mitochondrial morphology and function with novel fixable fluorescent stains.
Poot, M., Zhang, Y. Z., Krämer, J. A., Wells, K. S., Jones, L. J., Hanzel, D. K., Lugade, A. G., Singer, V. L., & Haugland, R. P. (1996) · Journal of Histochemistry & Cytochemistry · doi:10.1177/44.12.8985128 · Cited by 520
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471
Russell, A. P., Feilchenfeldt, J., Schreiber, S., Praz, M., Crettenand, A., Gobelet, C., Meier, C. A., Bell, D. R., Kralli, A., Giacobino, J.-P., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.12.2874 · Cited by 456
Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 453
Li, H.-H., Kedar, V., Zhang, C., McDonough, H., Arya, R., Wang, D.-Z., & Patterson, C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422220 · Cited by 430
Czubryt, M. P., McAnally, J., Fishman, G. I., & Olson, E. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337639100 · Cited by 418
Degradation of MyoD Mediated by the SCF (MAFbx) Ubiquitin Ligase
Tintignac, L. A., Lagirand, J., Batonnet, S., Sirri, V., Leibovitch, M. P., & Leibovitch, S. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411346200 · Cited by 405
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352
Effects of food deprivation on protein synthesis and degradation in rat skeletal muscles
Li, J., & Goldberg, A. (1976) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1976.231.2.441 · Cited by 287
Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy
Chen, Y. W., Nagaraju, K., Bakay, M., McIntyre, O., Rawat, R., Shi, R., & Hoffman, E. P. (2005) · Neurology · doi:10.1212/01.wnl.0000173836.09176.c4 · Cited by 276
Serrano, A. L., Murgia, M., Pallafacchina, G., Calabria, E., Coniglio, P., Lømo, T., & Schiaffino, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231148598 · Cited by 265
Toxicity of statins on rat skeletal muscle mitochondria
Kaufmann, P., Török, M., Zahno, A., Waldhauser, K. M., Brecht, K., & Krähenbühl, S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6235-z · Cited by 263
Baracos, V. E., DeVivo, C., Hoyle, D. H., & Goldberg, A. L. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.268.5.e996 · Cited by 263
Clinical Perspectives of Statin-Induced Rhabdomyolysis
Antons, K. A., Williams, C. D., Baker, S. K., & Phillips, P. S. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.007 · Cited by 238
Self-citationStatin-Induced Muscle Necrosis in the Rat: Distribution, Development, and Fibre Selectivity
Westwood, F. R., Bigley, A., Randall, K., Marsden, A. M., & Scott, R. C. (2005) · Toxicologic Pathology · doi:10.1080/01926230590908213 · Cited by 214
Molecular regulation of individual skeletal muscle fibre types
Spangenburg, E. E., & Booth, F. W. (2003) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.2003.01158.x · Cited by 211
O'Meara, J. G., Kardia, S. L. R., Armon, J. J., Brown, C. A., Boerwinkle, E., & Turner, S. T. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.12.1313 · Cited by 191
Muscle coenzyme Q10 level in statin-related myopathy
Lamperti, C., Naini, A. B., Lucchini, V., Prelle, A., Bresolin, N., Moggio, M., Sciacco, M., Kaufmann, P., & DiMauro, S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1709 · Cited by 178 · cited 1×
“Interestingly, CoQ 10 , a component of the inner mitochondrial membrane required for oxidative phosphorylation, is prenylated; thus, its synthesis is inhibited by statins (15–17).”
Endostatin is a potential inhibitor of Wnt signaling
Hanai, J., Gloy, J., Karumanchi, S. A., Kale, S., Tang, J., Hu, G., Chan, B., Ramchandran, R., Jha, V., Sukhatme, V. P., et al. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200203064 · Cited by 156
Self-citationThompson, P. D., Yurgalevitch, S. M., Flynn, M. M., Zmuda, J. M., Spannaus-Martin, D. J., Saritelli, A. L., Bausserman, L., & Herbert, P. N. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90305-x · Cited by 152
Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin
Pan, H., DeVault, A. R., Wang‐Iverson, D. B., Ivashkiv, E., Swanson, B. N., & Sugerman, A. A. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb01856.x · Cited by 146
Molecular clues into the pathogenesis of statin‐mediated muscle toxicity
Baker, S. K. (2005) · Muscle & Nerve · doi:10.1002/mus.20291 · Cited by 137
Flint, O. P., Masters, B. A., Gregg, R. E., & Durham, S. K. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1997.8131 · Cited by 132
Schaefer, W. H., Lawrence, J. W., Loughlin, A. F., Stoffregen, D. A., Mixson, L. A., Dean, D. C., Raab, C. E., Yu, N. X., Lankas, G. R., & Frederick, C. B. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.08.013 · Cited by 131
Muscular Side Effects of Statins
Sinzinger, H. F., Wolfram, R. M., & Peskar, B. A. (2002) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200208000-00001 · Cited by 127
Taylor, E. B., Lamb, J. D., Hurst, R. W., Chesser, D. G., Ellingson, W. J., Greenwood, L. J., Porter, B. B., Herway, S. T., & Winder, W. W. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2005 · Cited by 126
Altered responses in skeletal muscle protein turnover during aging in anabolic and catabolic periods
Attaix, D., Mosoni, L., Dardevet, D., Combaret, L., Mirand, P. P., & Grizard, J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.04.009 · Cited by 123
Bench to Bedside and Back Again: Personalizing Treatment for Patients with GIST
Godwin, A. K. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0709 · Cited by 109
The developmental program of fast myosin heavy chain expression in avian skeletal muscles
Crow, M. T., & Stockdale, F. E. (1986) · Developmental Biology · doi:10.1016/0012-1606(86)90002-3 · Cited by 108
Koo, S., Kucher, N., Fanikos, J., & Goldhaber, S. Z. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.346-b · Cited by 103
Adams, V., Linke, A. H.-P., Wisløff, U., DORING, C., Erbs, S., Kränkel, N., Witt, C. C., Labeit, S., Müller‐Werdan, U., & Schuler, G. C. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.026 · Cited by 101
Tiao, G. M., Lieberman, M. A., Fischer, J. E., & Hasselgren, P.-O. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.272.3.r849 · Cited by 96
Flint, O. P., Masters, B. A., Gregg, R. E., & Durham, S. K. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1997.8174 · Cited by 92
Statin myopathies: pathophysiologic and clinical perspectives.
Baker, S. K., & Tarnopolsky, M. A. (2001) · PubMed · Cited by 91
Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma: A Randomised Trial
Berthold, H. K., Naini, A., Mauro, S. D., Hallikainen, M., Gylling, H. K., Krone, W., & Gouni‐Berthold, I. (2006) · Drug Safety · doi:10.2165/00002018-200629080-00007 · Cited by 87
Roles of Exercise and Pharmacokinetics in Cerivastatin-Induced Skeletal Muscle Toxicity
Seachrist, J. L., Loi, C., Evans, M. G., Criswell, K. A., & Rothwell, C. E. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi305 · Cited by 82
Abrogation of Insulin-like Growth Factor-I (IGF-I) and Insulin Action by Mevalonic Acid Depletion
Siddals, K. W., Marshman, E., Westwood, M., & Gibson, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404838200 · Cited by 76
Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies
Holstein, S. A., Knapp, H. R., Clamon, G. H., Murry, D. J., & Hohl, R. J. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0013-8 · Cited by 74
Evenson, A. R., Fareed, M. U., Menconi, M. J., Mitchell, J. C., & Hasselgren, P.-O. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.06.002 · Cited by 72
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
Gadbut, A. P., Caruso, A. P., & Galper, J. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(95)92163-x · Cited by 68
Experimental Lovastatin Myopathy
Waclawik, A. J., Lindal, S., & Engel, A. G. (1993) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199309000-00012 · Cited by 67
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200216421 · Cited by 64
Statin myotoxicity is associated with changes in the cardiopulmonary function
Phillips, P. S., Phillips, C. T., Sullivan, M. J., Naviaux, R. K., & Haas, R. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.06.014 · Cited by 62
Self-citationNambudiri, A. M. D., Ranganathan, S., & Rudney, H. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70714-5 · Cited by 60
Matzno, S., Yamauchi, T., Gohda, M., Ishida, N., Katsuura, K., Hanasaki, Y., Tokunaga, T., Itoh, H., & Nakamura, N. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37182-0 · Cited by 50
Yang, H., Menconi, M. J., Wei, W., Petkova, V., & Hasselgren, P. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20371 · Cited by 49
Genetic screens for genes controlling motor nerve–muscle development and interactions
Birely, J., Schneider, V., Santana, E., Dosch, R., Wagner, D. S., Mullins, M. C., & Granato, M. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.01.012 · Cited by 44
Distal elements are critical for human CD34 expression in vivo
Okuno, Y., Huettner, C. S., Radomska, H. S., Petkova, V., Iwasaki, H., Akashi, K., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood-2002-03-0788 · Cited by 38
Bdolah, Y., Segal, A. M., Tanksale, P., Karumanchi, S. A., & Lecker, S. H. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00617.2006 · Cited by 34
Self-citationExertion-induced rhabdomyolysis in a patient on statin therapy
Unnikrishnan, D., & Satish, B. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh578 · Cited by 18
Rokach, A. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460720 · Cited by 17
Cited by
Cellular cholesterol trafficking and compartmentalization
Ikonen, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2336 · Cited by 1,462
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1
Bodine, S. C., & Baehr, L. M. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00204.2014 · Cited by 1,113
The role of exercise and PGC1α in inflammation and chronic disease
Handschin, C., & Spiegelman, B. M. (2008) · Nature · doi:10.1038/nature07206 · Cited by 1,083
Signaling in Muscle Atrophy and Hypertrophy
Sandri, M. (2008) · Physiology · doi:10.1152/physiol.00041.2007 · Cited by 827
Metadata
- Authors
- Hanai, J.-I., Cao, P., Tanksale, P., Imamura, S., Koshimizu, E., Zhao, J., Kishi, S., Yamashita, M., Phillips, P. S., Sukhatme, V. P., & Lecker, S. H.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-11-08
- Volume
- 117
- Issue
- 12
- Pages
- 3940-51
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2115000268
- Cited by
- 281
- References
- 77
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.